Top

Published in:

01-11-2013 | Original Paper

Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study

Authors: Imo E. Hoefer, Jan-Willem Sels, J. Wouter Jukema, Sandrin Bergheanu, Erik Biessen, Elizabeth McClellan, Mat Daemen, Pieter Doevendans, Philip de Groot, Marieke Hillaert, Sebastiaan Horsman, Mustafa Ilhan, Johan Kuiper, Nico Pijls, Ken Redekop, Peter van der Spek, Andrew Stubbs, Eric van de Veer, Johannes Waltenberger, Anton-Jan van Zonneveld, Gerard Pasterkamp

Published in: Clinical Research in Cardiology | Issue 11/2013

Abstract

Biomarkers for primary or secondary risk prediction of cardiovascular disease (CVD) are urgently needed to improve individual treatment and clinical trial design. The vast majority of biomarker discovery studies has concentrated on plasma/serum as an easily accessible source. Although numerous markers have been identified, their added predictive value on top of traditional risk factors has been limited, as the biological specimen does not specifically reflect expression profiles related with CVD progression and because the signal is often diluted by marker release from other organs. In contrast to serum markers, circulating cells serve as indicators of the actual disease state due to their active role in the pathogenesis of CVD and are responsible for the majority of secreted biomarkers. Therefore, the CIRCULATING CELLS study was initiated, focusing on the cellular effectors of atherosclerosis in the circulation. In total, 714 patients with coronary artery disease (CAD) symptoms were included. Blood cell fractions (monocytes, T-lymphocytes, platelets, granulocytes, PBMC) of all individual patients were isolated and stored for analysis. Concomitantly, extensive flow cytometric characterization of these populations was performed. From each patient, a detailed clinical profile together with extensive questionnaires about medical history and life style was obtained. Various high-throughput -omics approaches (protein, mRNA, miRNA) are currently being undertaken. Data will be integrated with advanced bioinformatics for discovery and validation of secondary risk markers for adverse events. Overall, the CIRCULATING CELLS study grants the interesting possibility that it will both identify novel biomarkers and provide useful insights into the pathophysiology of CAD in patients.

Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367(14):1310–1320PubMedCrossRef

Sever PS, Chang CL, Prescott MF, Gupta A, Poulter NR, Whitehouse A, Scanlon M (2012) Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Eur Heart J 33(23):2970–2979PubMedCrossRef

Dadu RT, Nambi V, Ballantyne CM (2012) Developing and assessing cardiovascular biomarkers. Transl Res 159(4):265–276PubMedCrossRef

Fava C, Montagnana M, Guidi GC, Melander O (2012) From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population. Ann Med 44(5):433–447PubMedCrossRef

Lok DJ, Lok SI, de la Bruggink-André Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res cardiol 102:103–110. doi:10.1007/s00392-012-0500-y PubMedCrossRef

Balın M, Celik A, Kobat MA (2012) Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with proximal/middle segment of the LAD lesions in patients with stable coronary artery disease. Clin Res cardiol 101:247–253. doi:10.1007/s00392-011-0386-0 PubMedCrossRef

Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355(25):2631–2639PubMedCrossRef

Hellings WE, Moll FL, De Vries JP, Ackerstaff RG, Seldenrijk KA, Met R, Velema E, Derksen WJ, De Kleijn DP, Pasterkamp G (2008) Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. JAMA 299(5):547–554PubMedCrossRef

Verhoeven BA, Velema E, Schoneveld AH, de Vries JP, de Bruin P, Seldenrijk CA, de Kleijn DP, Busser E, van der Graaf Y, Moll F, Pasterkamp G (2004) Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 19(12):1127–1133PubMedCrossRef

10.

Kang J-G, Patino WD, Matoba S, Hwang PM (2006) Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med 16:163–168PubMedCrossRef

11.

Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508–519PubMedCrossRef

12.

Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54(23):2129–2138PubMedCrossRef

13.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108(14):1664–1672PubMedCrossRef

14.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108(15):1772–1778PubMedCrossRef

15.

Balconi G, Lehmann R, Fiordaliso F, Assmus B, Dimmeler S, Sarto P, Carbonieri E, Gualco A, Campana C, Angelici L (2009) Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure. J Cardiac Fail 15:747–755CrossRef

16.

Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM (2005) Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22):2981–2987PubMedCrossRef

17.

Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353(10):999–1007PubMedCrossRef

18.

Ka Volaklis, Tokmakidis SP, Halle M (2013) Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients. Clin Res Cardiol 102:249–257. doi:10.1007/s00392-012-0517-2 CrossRef

19.

Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Kohler H, Girndt M (2008) CD14(++)CD16 + monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 73(5):622–629PubMedCrossRef

20.

Ulrich C, Heine GH, Seibert E, Fliser D, Girndt M (2010) Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant 25:2265–2272PubMedCrossRef

21.

Alber HF, Duftner C, Wanitschek M, Dörler J, Schirmer M, Suessenbacher A, Frick M, Dichtl W, Pachinger O, Weidinger F (2009) Neopterin, CD4 + CD28 − lymphocytes and the extent and severity of coronary artery disease. Int J Cardiol 135:27–35PubMedCrossRef

22.

Dumitriu IE, Araguas ET, Baboonian C, Kaski JC (2009) CD4 + CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 81(1):11–19PubMedCrossRef

23.

Giubilato S, Liuzzo G, Brugaletta S, Pitocco D, Graziani F, Smaldone C, Montone RA, Pazzano V, Pedicino D, Biasucci LM, Ghirlanda G, Crea F (2011) Expansion of CD4 + CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 32(10):1214–1226PubMedCrossRef

24.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972PubMedCrossRef

25.

Sinning C, Lillpopp L, Appelbaum S, Ojeda F, Zeller T, Schnabel R, Lubos E, Jagodzinski A, Keller T, Munzel T, Bickel C, Blankenberg S (2013) Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol. doi:10.1007/s00392-013-0555-4

26.

Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227PubMed

27.

Bleijerveld OB, Wijten P, Cappadona S, McClellan EA, Polat AN, Raijmakers R, Sels JW, Colle L, Grasso S, van den Toorn HW, van Breukelen B, Stubbs A, Pasterkamp G, Heck AJ, Hoefer IE, Scholten A (2012) Deep proteome profiling of circulating granulocytes reveals bactericidal/permeability-increasing protein as a biomarker for severe atherosclerotic coronary stenosis. J Proteome Res. doi:10.1021/pr3004375 PubMed

28.

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516PubMedCrossRef

29.

Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360(3):213–224PubMedCrossRef

30.

Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A (2002) Management of acute coronary syndromes. variations in practice and outcome; findings from the global registry of acute coronary events (GRACE). Eur Heart J 23(15):1177–1189PubMedCrossRef

31.

Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A (2002) A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23(15):1190–1201PubMedCrossRef

32.

Sanchez-Margalet V, Cubero JM, Martin-Romero C, Cubero J, Cruz-Fernandez JM, Goberna R (2004) Expression of activation molecules in neutrophils, monocytes and lymphocytes from patients with unstable angina treated with stent implantation. Clin Chem Lab Med 42(3):273–278PubMedCrossRef

33.

Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I (2002) Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105(18):2166–2171PubMedCrossRef

34.

Gurbel PA, Bliden KP, Hayes KM, Tantry U (2004) Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2(4):535–545PubMedCrossRef

35.

Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, Lackner KJ, Iz M, Meyer J, Darius H, Rupprecht HJ (2004) CD14 + CD16 + monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 92(2):419–424PubMed

36.

Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115(12):3378–3384PubMedCrossRef

37.

Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J (2005) Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111(20):2654–2661PubMedCrossRef

38.

von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100(1):27–40CrossRef

39.

Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102(2):209–217PubMedCrossRef

40.

Brambilla M, Camera M, Colnago D, Marenzi G, De Metrio M, Giesen PL, Balduini A, Veglia F, Gertow K, Biglioli P, Tremoli E (2008) Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 28(5):947–953PubMedCrossRef

41.

Shantsila E, Lip GY (2009) Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 29(10):1433–1438PubMedCrossRef

42.

Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Takeshita T, Akasaka T (2010) Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 212(2):628–635PubMedCrossRef

43.

Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, Van Der Bom JG (2010) High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J Thromb Haemost 8(5):906–913PubMed

44.

Ley K, Miller YI, Hedrick CC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31(7):1506–1516PubMedCrossRef

45.

Linden MD, Jackson DE (2010) Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 42(11):1762–1766PubMedCrossRef

46.

Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TCTM, Moerland PD, Volger OL, Baggen JM, Böhm M, Piek JJ, Horrevoets AJG, van Royen N (2009) Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mole Cell Cardiol 46(2):177–185. doi:10.1016/j.yjmcc.2008.10.029 CrossRef

47.

Ardigo D, CaJM Gaillard, Braam B (2007) Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clinical chem and lab med 45:1109–1120

48.

Horwitz PA, Tsai EJ, Putt ME, Gilmore JM, Lepore JJ, Parmacek MS, Kao AC, Desai SS, Goldberg LR, Brozena SC, Jessup ML, Epstein JA, Cappola TP (2004) Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110(25):3815–3821PubMedCrossRef

49.

Ma J, Liew CC (2003) Gene profiling identifies secreted protein transcripts from peripheral blood cells in coronary artery disease. J Mol Cell Cardiol 35(8):993–998PubMedCrossRef

50.

Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B, Trout HH 3rd, Kozloff L, Hwang PM (2005) Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci USA 102(9):3423–3428PubMedCrossRef

51.

Moore DF, Li H, Jeffries N, Wright V, Cooper RA Jr, Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H, Goldin E, Baird AE (2005) Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 111(2):212–221PubMedCrossRef

52.

Empana JP, Canoui-Poitrine F, Luc G, Juhan-Vague I, Morange P, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Ducimetiere P (2008) Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 29(16):1966–1974. doi:10.1093/eurheartj/ehn331 ehn331 [pii]PubMedCrossRef

53.

Lindmark E, Diderholm E, Wallentin L, Siegbahn A (2001) Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286(17):2107–2113PubMedCrossRef

54.

Tziakas DN, Chalikias GK, Tentes IK, Stakos D, Chatzikyriakou SV, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H (2008) Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J 29(22):2713–2722PubMedCrossRef

55.

Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94(5):874–877PubMedCrossRef

56.

Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-Maj E, Kobielusz-Gembala I (2003) Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis 14(6):431–438PubMedCrossRef

Title: Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study
Authors: Imo E. Hoefer
Jan-Willem Sels
J. Wouter Jukema
Sandrin Bergheanu
Erik Biessen
Elizabeth McClellan
Mat Daemen
Pieter Doevendans
Philip de Groot
Marieke Hillaert
Sebastiaan Horsman
Mustafa Ilhan
Johan Kuiper
Nico Pijls
Ken Redekop
Peter van der Spek
Andrew Stubbs
Eric van de Veer
Johannes Waltenberger
Anton-Jan van Zonneveld
Gerard Pasterkamp
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 11/2013
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0607-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2013

Reperfusion therapy and mortality in octogenarian STEMI patients: results from the Belgian STEMI registry

Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group

Exaggerated increase of exercise-induced pulmonary artery pressure in systemic sclerosis patients predominantly results from left ventricular diastolic dysfunction

Bypass to the left coronary artery system may accelerate left main coronary artery negative remodeling and calcification

The revised EuroSCORE II for the prediction of mortality in patients undergoing transcatheter aortic valve implantation

Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page